Format

Send to

Choose Destination
J Comp Eff Res. 2018 Jul;7(7):685-691. doi: 10.2217/cer-2017-0081. Epub 2018 May 29.

Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.

Author information

1
Comprehensive Health Insights, Louisville, KY 40202, USA.
2
Boehringer Ingelheim, Ridgefield, CT 06877, USA.
3
Humana Inc., Louisville, KY 40202, USA.

Abstract

Factors influencing differences in persistence between dabigatran and warfarin in patients with nonvalvular atrial fibrillation (NVAF) remain unclear.

AIM:

Compare differences in persistence between new dabigatran and warfarin users in patients newly diagnosed with NVAF, adjusting for sociodemographics, clinical characteristics, patient out-of-pocket cost and other covariates.

METHODS:

A retrospective matched-cohort study was conducted using a US claims database of Medicare and commercially insured patients with NVAF aged≥ 18 years. Persistence and monthly out-of-pocket costs for dabigatran or warfarin were calculated and adjusted for covariates using Cox proportional hazard models.

RESULTS & CONCLUSION:

Unadjusted persistence was significantly lower among dabigatran users (n = 1025) compared with matched warfarin users (38 vs 46%). Adjusting for covariates rendered this difference insignificant (hazard ratio = 0.930).

KEYWORDS:

dabigatran; nonvalvular atrial fibrillation; out of pocket cost; persistence; warfarin

PMID:
29808717
DOI:
10.2217/cer-2017-0081

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center